WuXi
((Traduction automatisée par Reuters, veuillez consulter la clausede non-responsabilité https://bit.ly/rtrsauto))
La société chinoise WuXi AppTec
603259.SS a déclaré mardi que ses filiales avaient signé unaccord avec la société américaine de capital-investissementAltaris LLC pour la vente de son unité de production de thérapiecellulaire et génique, WuXi Advanced Therapies, pour un montantnon divulgué.
© 2024 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.
